Opinion - (2025) Volume 11, Issue 6
Received: 01-Dec-2025, Manuscript No. antimicro-26-183060;
Editor assigned: 03-Dec-2025, Pre QC No. P-183060;
Reviewed: 17-Dec-2025, QC No. Q-183060;
Revised: 22-Dec-2025, Manuscript No. R-183060;
Published:
29-Dec-2025
Citation: Mokoena, Thabo. ”Novel Strategies To Combat Hospital-Acquired Infections.” J Antimicrob Agents 11 (2025):435.
Copyright: © 2025 Mokoena T. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
The escalating global health crisis of antimicrobial resistance (AMR) necessitates urgent and innovative interventions, particularly within hospital settings where the incidence of hospital-acquired infections (HAIs) remains a significant concern. The development of novel antimicrobial agents is paramount to counter the increasing prevalence of resistant pathogens that evade conventional therapeutic strategies. The growing threat of hospital-acquired infections (HAIs) necessitates the development of novel antimicrobial agents. This article explores emerging strategies targeting resistant pathogens, including phages, antimicrobial peptides, and innovative small molecules. Understanding their mechanisms of action and potential for clinical translation is crucial for combating the escalating crisis of antimicrobial resistance [1].
Bacteriophage therapy, a long-established yet recently revitalized approach, presents a compelling alternative to current antibiotics. Its remarkable specificity and ability to evolve alongside bacterial resistance mechanisms offer a promising avenue for treating infections that have become intractable to standard treatments. Bacteriophage therapy presents a promising alternative to conventional antibiotics for treating difficult-to-treat HAIs. This review details recent advancements in phage discovery, engineering, and clinical applications, highlighting their specificity and ability to overcome antibiotic resistance mechanisms [2].
Antimicrobial peptides (AMPs), integral components of the innate immune system, are increasingly recognized for their therapeutic potential against bacterial infections. Their broad-spectrum activity and novel mechanisms of action make them attractive candidates for combating multidrug-resistant organisms. Antimicrobial peptides (AMPs) are a critical component of the innate immune system and are being explored as novel therapeutic agents for HAIs. This study focuses on the design and evaluation of synthetic AMPs with enhanced activity against multidrug-resistant bacteria [3].
The emergence of carbapenem-resistant Enterobacteriaceae (CRE) represents a critical challenge in modern healthcare, rendering many life-saving antibiotics ineffective. Novel strategies are urgently required to address this growing threat and restore the efficacy of existing treatments. The emergence of carbapenem-resistant Enterobacteriaceae (CRE) poses a significant challenge in healthcare settings. This research investigates novel therapeutic approaches, including combination therapies and efflux pump inhibitors, to restore susceptibility to existing antibiotics [4].
Modulating bacterial communication systems, such as quorum sensing (QS), offers a sophisticated approach to combatting infections by disarming bacteria rather than outright killing them. This strategy aims to reduce virulence and enhance host defenses. This article examines the potential of quorum sensing inhibitors as a novel strategy to disarm virulent bacteria, thereby reducing their pathogenicity and susceptibility to host defenses, offering a new avenue for HAI management [5].
Repurposing existing drugs that have already undergone rigorous safety testing provides a faster and more cost-effective route to developing new treatments for HAIs. This approach can rapidly address emerging resistance patterns. The paper explores the repurposing of existing drugs for the treatment of HAIs, a cost-effective approach that can rapidly provide new therapeutic options against challenging pathogens, including those with emerging resistance profiles [6].
Nanotechnology offers innovative delivery systems for antimicrobial agents, particularly for combating biofilms, which are notoriously difficult to eradicate. Nanoparticles can enhance drug penetration and efficacy at infection sites. This research investigates the efficacy of nanoparticles loaded with antimicrobial agents against biofilms, a major contributor to persistent HAIs. The study highlights the enhanced penetration and killing capabilities of these nanocarriers [7].
Gene-editing technologies, such as CRISPR-Cas systems, provide a highly precise method for targeting specific bacterial genes responsible for resistance or virulence. This precision minimizes disruption to the host microbiome. The article discusses the role of CRISPR-based antimicrobials in targeting specific genes responsible for antibiotic resistance or virulence, offering a precision approach to combatting HAIs and minimizing collateral damage to the microbiome [8].
The increasing global threat of polymyxin resistance, a critical class of last-resort antibiotics, demands the development of new strategies to manage infections caused by resistant Gram-negative bacteria. This review highlights the increasing prevalence of polymyxin resistance and explores emerging strategies, including novel polymyxin derivatives and combination therapies, to combat infections caused by Gram-negative bacteria resistant to last-resort antibiotics [9].
Combining existing antibiotics with novel agents, such as small molecule inhibitors, can restore susceptibility in multidrug-resistant bacteria. This synergistic approach aims to prolong the effectiveness of current therapeutic arsenals. The study investigates the synergistic effects of combining existing antibiotics with novel agents, such as small molecule inhibitors, to resensitize multidrug-resistant bacteria to established treatments, offering a viable strategy to extend the lifespan of current therapeutics [10].
The persistent challenge of hospital-acquired infections (HAIs) necessitates a continuous exploration of novel therapeutic modalities beyond traditional antibiotics. Emerging strategies aim to circumvent existing resistance mechanisms and provide effective treatment options for increasingly recalcitrant pathogens. This review consolidates recent advancements in this critical field. The growing threat of hospital-acquired infections (HAIs) necessitates the development of novel antimicrobial agents. This article explores emerging strategies targeting resistant pathogens, including phages, antimicrobial peptides, and innovative small molecules. Understanding their mechanisms of action and potential for clinical translation is crucial for combating the escalating crisis of antimicrobial resistance [1].
Bacteriophage therapy is undergoing a significant renaissance, offering a highly specific and adaptable approach to treating bacterial infections. Recent progress in phage isolation, genetic engineering, and clinical trial design underscores its potential to address the limitations of conventional antibiotics, particularly against multidrug-resistant strains. Bacteriophage therapy presents a promising alternative to conventional antibiotics for treating difficult-to-treat HAIs. This review details recent advancements in phage discovery, engineering, and clinical applications, highlighting their specificity and ability to overcome antibiotic resistance mechanisms [2].
Antimicrobial peptides (AMPs) represent a cornerstone of the innate immune response and are being actively investigated as next-generation antimicrobials. Research efforts are focused on designing synthetic AMPs with enhanced stability, potency, and spectrum of activity against resistant bacterial species. Antimicrobial peptides (AMPs) are a critical component of the innate immune system and are being explored as novel therapeutic agents for HAIs. This study focuses on the design and evaluation of synthetic AMPs with enhanced activity against multidrug-resistant bacteria [3].
The increasing prevalence of carbapenem-resistant Enterobacteriaceae (CRE) demands innovative therapeutic strategies. This research focuses on methods to restore the susceptibility of these formidable pathogens to existing antibiotics, exploring avenues such as combination therapies and inhibitors of resistance mechanisms. The emergence of carbapenem-resistant Enterobacteriaceae (CRE) poses a significant challenge in healthcare settings. This research investigates novel therapeutic approaches, including combination therapies and efflux pump inhibitors, to restore susceptibility to existing antibiotics [4].
Quorum sensing (QS) inhibitors offer a paradigm shift in antimicrobial therapy by targeting bacterial communication and virulence factors rather than direct killing. This approach aims to disarm pathogens, making them more susceptible to host defenses and reducing the selective pressure for resistance development. This article examines the potential of quorum sensing inhibitors as a novel strategy to disarm virulent bacteria, thereby reducing their pathogenicity and susceptibility to host defenses, offering a new avenue for HAI management [5].
Drug repurposing presents a pragmatic and expedited pathway for discovering new treatments for HAIs. By identifying new indications for existing, safety-tested pharmaceuticals, this strategy can rapidly provide viable therapeutic options against emerging resistant pathogens. The paper explores the repurposing of existing drugs for the treatment of HAIs, a cost-effective approach that can rapidly provide new therapeutic options against challenging pathogens, including those with emerging resistance profiles [6].
Nanotechnology-based delivery systems are showing significant promise in enhancing the efficacy of antimicrobials, particularly in combating recalcitrant biofilms associated with chronic HAIs. These systems can improve drug delivery and penetration into biofilm structures. This research investigates the efficacy of nanoparticles loaded with antimicrobial agents against biofilms, a major contributor to persistent HAIs. The study highlights the enhanced penetration and killing capabilities of these nanocarriers [7].
CRISPR-based antimicrobials represent a cutting-edge technology for precision targeting of bacterial genes essential for survival or resistance. This approach offers the potential for highly specific antimicrobial activity with minimal impact on the commensal microbiome. The article discusses the role of CRISPR-based antimicrobials in targeting specific genes responsible for antibiotic resistance or virulence, offering a precision approach to combatting HAIs and minimizing collateral damage to the microbiome [8].
The growing challenge of polymyxin resistance, particularly among Gram-negative bacteria, requires urgent attention. Emerging strategies focus on developing novel polymyxin derivatives and synergistic combinations to overcome resistance to these last-resort antibiotics. This review highlights the increasing prevalence of polymyxin resistance and explores emerging strategies, including novel polymyxin derivatives and combination therapies, to combat infections caused by Gram-negative bacteria resistant to last-resort antibiotics [9].
Synergistic combination therapies involving novel agents and existing antibiotics are crucial for resensitizing multidrug-resistant bacteria. This approach aims to restore the efficacy of older drugs and extend the therapeutic lifespan of our current antibiotic arsenal. The study investigates the synergistic effects of combining existing antibiotics with novel agents, such as small molecule inhibitors, to resensitize multidrug-resistant bacteria to established treatments, offering a viable strategy to extend the lifespan of current therapeutics [10].
Hospital-acquired infections (HAIs) pose a significant and growing threat due to antimicrobial resistance. Novel strategies are urgently needed to combat these infections. Emerging approaches include bacteriophage therapy, which offers specificity and adaptability against resistant pathogens. Antimicrobial peptides (AMPs) are being developed as next-generation agents with unique mechanisms of action. Research is also focused on overcoming resistance in critical pathogens like carbapenem-resistant Enterobacteriaceae (CRE) through combination therapies and efflux pump inhibitors. Targeting bacterial communication via quorum sensing inhibitors presents a way to disarm bacteria. Drug repurposing offers a cost-effective and rapid route to new treatments. Nanoparticles are being utilized to enhance antimicrobial delivery, especially against biofilms. CRISPR-based antimicrobials provide a precise approach to target resistance genes. Addressing polymyxin resistance through new derivatives and combinations is also a key area. Finally, synergistic combinations of existing and novel agents are crucial for resensitizing multidrug-resistant bacteria and extending the utility of current therapeutics. These diverse strategies collectively aim to provide new tools in the fight against HAIs.
None
None
Journal of Antimicrobial Agents received 444 citations as per Google Scholar report
